key: cord-0973696-nl90t2tj
authors: Nersesjan, V.; Amiri, M.; Christensen, H. K.; Benros, M. E.; Kondziella, D.
title: 30-day mortality and morbidity in COVID-19 versus influenza: A populationbased study
date: 2020-07-28
journal: nan
DOI: 10.1101/2020.07.25.20162156
sha: 2c5bf8dc853c4c700be974d1891713865b939ecb
doc_id: 973696
cord_uid: nl90t2tj

Background As of July 2020, COVID-19 has caused 500,000 deaths worldwide. However, large-scale studies of COVID-19 mortality and new-onset comorbidity compared to influenza and individuals tested negative for COVID-19 are lacking. We aimed to investigate COVID-19 30-day mortality and newonset comorbidity compared to individuals with negative COVID-19 test results and individuals tested for influenza. Methods and findings This population-based cohort study utilized electronic health records covering roughly half (n=2,647,229) of Denmark's population, with nationwide linkage of microbiology test results and death records. All individuals [≥]18 years tested for COVID-19 and individuals tested for influenza were followed from November 1, 2017 to June 30, 2020. The main outcome was 30-day mortality after a test for either COVID-19 or influenza. Secondary outcomes were major comorbidity diagnoses 30-days after the test for either COVID-19 or influenza. In total, 224,639 individuals were tested for COVID-19. Among inpatients positive for COVID-19, 356 of 1657 (21%) died within 30 days, which was a 3.0 to 3.1-fold increased 30-day mortality rate, when compared to influenza and COVID-19-negative inpatients (all p<0.001). For outpatients, 128 of 6,263 (2%) COVID-19-positive patients died within 30 days, which was a 5.5 to 6.9-fold increased mortality rate compared to influenza and COVID-19-negative patients, respectively (all p<0.001). Compared to hospitalized patients with influenza, new-onset ischemic stroke, diabetes and nephropathy occurred more frequently in inpatients with COVID-19 (all p<0.05). Conclusions In this population-based study comparing COVID-19 with influenza, COVID-19 was associated with increased rates of major systemic and vascular comorbidity and substantially higher mortality, which is likely even higher than the stated 3.0 to 5.5-fold increase owing to more extensive testing for COVID-19.

COVID-19 has led to a worldwide healthcare crisis with >10,000,000 confirmed infected people, resulting in >500,000 deaths as of July 2020. 1, 2 Governmental initiatives including lockdowns and social distancing are aiming to restrict the spread of the virus. However, critical voices 3 have argued the socioeconomic consequences may be unjustified given that little is known about how the pandemic compares with annual influenza epidemics in terms of mortality and morbidity. According to the WHO, seasonal influenza may result in 290,000-650,000 deaths worldwide annually, 4,5 but substantially higher mortality rates for COVID-19 might have even more adverse impact on global health without strict preventive measures.

Of further concern, COVID-19 might not only be a respiratory disease but a multi-organ disorder because of the wide expression of the angiotensin-converting enzyme-2 receptor to which SARS-Cov-2 binds, 6 leading among others to thromboembolic complications, 7 severe inflammatory responses 8 and possibly diabetes. 9 Neurological and psychiatric complications will likely constitute a major health burden as well. 10, 11 But how COVID-19 morbidity compares to influenza morbidity is equally poorly understood.

Here, for the first time, we utilized population-based electronic health records (EHR) from Denmark linked with nationwide databases on test results for infections and death records, to investigate mortality in people with COVID-19 compared to people with influenza and to people tested negative for COVID-19. For secondary outcomes we estimated COVID-19associated new-onset comorbidity, including cardiovascular, neurological and psychiatric events, compared to influenza and individuals tested COVID-19-negative. Analyses were stratified according to age and in-and outpatient status. We hypothesized that COVID-19 would be associated with higher mortality and increased rates of novel comorbidities compared to influenza A/B.

This retrospective Danish study was based on EHR covering two well-defined administrative regions: Capital Region (i.e. Greater Copenhagen and Bornholm) and Region 5 populations.

New-onset (i.e. 30 days after COVID-19 or influenza test) comorbidity diagnoses, including neurological, psychiatric and cardiovascular disease, pulmonary embolism, venous thrombosis, renal failure, diabetes and rheumatoid arthritis, in all populations. ICD-10 codes are listed in eTable 1.

Anonymized retrospective aggregate-level data on sex, age, prior comorbidities and population mortality 30 days after test results were extracted for individuals ≥18 years for each population, using the EPIC Slicer-Dicer function. For search strategies see eTable 1.

As individuals could be tested multiple times, individuals were only included in the COVID-19-negative, respectively, influenza-negative populations, when all their tests had been negative. Individuals tested for influenza during March 1-June 1, 2020 (i.e. FLU- 19) were included for sensitivity analysis (see below). To avoid overlap, we removed COVID-19-positive individuals from the FLU-19 population.

Main analysis was the relative risk (RR) of mortality rates 30 days after a test, in the overall populations and stratified according to in-and outpatient status and age. Secondary analysis was RR of cumulative 30 days post-test incidence of new-onset comorbidities, after exclusion of individuals who already had the investigated comorbidity before the test. We compared COVID-19 positive with COVID-19-negative and influenza-positive individuals.

To validate mortality data, absolute mortality rates extracted from electronic health records (EPIC) were compared with official Danish statistics numbers (eTable 2). Sensitivity analysis was conducted by comparing individuals ≥18 years with a positive or negative influenza test from the same time period as the COVID-19 population, i.e. March 1-June 1, 2020 , in order to investigate the possible influence of the COVID-19 pandemic, including lockdown and social distancing measures, on mortality rates in individuals tested for influenza. Chi-squared statistics were used to calculate odds ratio (OR), RR and 95% confidence intervals (CI) using SPSS (version 25; IBM, Armonk, NY, USA). Two-sided p≤0.05 was considered significant.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 28, 2020. http://www.nvk.dk/english). Use of anonymized aggregate-level data was approved by the Danish Data Protection Agency. Results from ≤5 patients were displayed as "≤5" to ensure data privacy.

A total of 224,639 individuals of any age were tested for SARS-CoV-2 between March 1-June 1, 2020; positive results were found in 7,920 individuals ≥18 years (i.e. our case population Table 1 and eTables 3-5. The proportion of inpatients at the time of COVID-19 or influenza tests was lower in the COVID-19-positive (20.9%) and the COVID-19-negative (16.6%) populations compared to influenza-positive (50%) and influenza-negative (57.7%) populations. We therefore analyzed mortality and comorbidities both in the overall populations and stratified according to in-and outpatient status and age.

Overall 30-day mortality in COVID-19-positive individuals was 484 of 7,920 (6.1%), whereas 30-day mortality for COVID-19-negative individuals was 2,654 of 189,883 (1.4%), corresponding to an increased mortality by RR 4.37 (95% CI=3.98-4.80). Table 2 and eTable 6 for a full outline of inpatient mortality rates stratified according to age groups. Figure 2 and eTable 6-9 show details.

The 30-day mortality rates for outpatients with COVID-19 were 20/62,701 (0.03%), 33/1,043 (3.2%) and 92/401 (22.9%) for age groups 40-59, 60-80 and >80 years, respectively. The corresponding numbers for COVID-19 negative individuals were 161/33,166 (0.5%) and 288/7,874 (3.7%) in the age groups 60-80 and >80 years, and for influenza-positive individuals ≤5/1,761 and 20/415 (4.8%), respectively. The case numbers were too low in the remaining age groups for statistics. See Table 2 and eTable 6 for full details of outpatient mortality rates stratified according to age.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 28, 2020. 

Pulmonary embolism 30 days after testing was more frequent in COVID-19-positive compared to COVID-19-negative individuals (RR 2.47 (95% CI=1.60-3.78)), eTable 10.

Diabetes and renal failure were also more frequent in COVID-19-positive compared to negative individuals (0.6% vs. 0.2% and 0.6% vs. 0.1%, respectively; both p<0.001).

Neurological disorders (excluding vascular disorders) and ischemic heart disease were less frequent in COVID-19-positive than in COVID-19-negative people (0.2% vs. 0.5% and 0.1% vs. 0.3%, respectively; both p< 0.05). Rates of new-onset cerebrovascular disorders, venous thrombosis and psychiatric disorders were not significantly different between the two populations.

Incident ischemic stroke 30 days after a test was more frequent in COVID-19-positive inpatients compared to those with influenza, RR 3.10 (95% CI=1.56-6.08), eTable 11. Newonset diabetes and nephropathy were more frequent in COVID-19 positive compared to influenza-positive inpatients (1.9% vs. 1.2% and 1.8% vs. 0.9% respectively; both p< 0.05).

Rates of new-onset pulmonary embolism, neurological disorders and psychiatric disorders were not statistically different.

Incidence diagnoses 30 days after positive tests in outpatients yielded either too low numbers for meaningful statistics or were not statistically different (eTable 11).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 28, 2020. . https://doi.org/10.1101/2020.07.25.20162156 doi: medRxiv preprint 9

The COVID-19-positive population was compared to a population of influenza-tested individuals from the same time period, March 1-June 1, 2020, i.e. outside the influenza peak season . In total, 12,502 people were tested for influenza A/B (56% inpatients; 566 positive and 8,318 negative). Inpatient mortality in FLU-19-positive and -negative populations was 26/317 (8.2%), respectively, 578/5058 (11.4%). Inpatient mortality was significantly increased in COVID-19 compared to FLU-19-positive and -negative individuals (RR 2.62 (95% CI=1.79-3.83), respectively, RR 1.88 (95% CI=1.67-2.12); both p<0.001).

To our knowledge, this is the first population-based study comparing mortality rates and new-onset comorbidities of COVID-19 patients with those of influenza patients and COVID-19-negative controls. 30-day mortality was 3.0 to 6.9-fold higher in the positive COVID-19 population compared to influenza and COVID-19-negative control populations.

The largest difference in mortality between COVID-19 and influenza was observed in outpatients. Equally important, new-onset ischemic stroke, renal failure and diabetes occurred at increased rates in COVID-19-positive inpatients compared to influenza patients.

Previous studies have reported widely varying overall COVID-19 mortality rates, e.g. 1.4% among 1099 cases in Wuhan, China, 14 and 7.2% among 22,512 in Italy. 15 In our study, the overall 30-day COVID-19 mortality was 6.1%, which is well in line with previous data from COVID-19 patients from Denmark. 16 Importantly, mortality rates are very different among in-and outpatients. In the COVID-19-positive inpatient population 30-day mortality was 21%, corresponding well again with a mortality of 28% in 191 inpatients reported by Zhou et al., 17 respectively, a median 14-day mortality of 26% in 140 inpatients from Xie et al. 18 These numbers are much higher than the 2% mortality in outpatients (i.e. individuals from the general public not requiring hospitalization) in the present study, indicating that, not surprisingly, inpatients with COVID-19 are doing worse than outpatients.

Compared to influenza and COVID-19-negative populations, COVID-19 30-day mortality was increased 3.0 to 3.10-fold for inpatients and 5.5 to 6.9-fold for outpatients. This is somewhat in contrast with an estimated 20-fold mean increase of COVID-19 mortality compared to influenza, based on indirect estimated numbers from the general public in the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 28, 2020. . https://doi.org/10.1101/2020.07.25.20162156 doi: medRxiv preprint 10 US. 19 This discrepancy could be explained by the higher proportion of sick individuals in our influenza tested populations. If testing for influenza A/B in Denmark had been equally widespread as for COVID-19, the excess COVID-19 mortality gap would likely have been even larger. As expected, mortality in COVID-19-positive patients was lowest in the young and highest in the elderly.

Thromboembolic complications in COVID-19 are assumed to be frequent. 20 New-onset ischemic stroke was indeed more frequent in COVID-19 than in influenza inpatients.

Increased rates of ischemic stroke in COVID-19 compared to influenza were also found in another study based on retrospective medical charts review from 2 academic centers in New York. 21 Given that signs and symptoms of strokeespecially minor strokemay be obscured by systemic illness as well as sedation and ventilation, the true risk may even be higher than the 3-to 7-fold increase reported here and in the cited work. 21 We also found that the risk of new-onset diabetes was 3-fold elevated in COVID-19-positive individuals compared to negative controls and 2-fold elevated compared to influenza-positive patients.

These results substantiate concerns of diabetogenic effects of COVID-19, 22 including the possibility of ketoacidosis. 23 Similarly, nephropathy was frequent in our COVID-19 population, and renal failure may lead to more complications and higher in-hospital mortality. 24 Ischemic heart disease appeared equally prevalent in inpatients with COVID-19 and those with influenza. Finally, pulmonary embolism occurred more often in our COVID-19 positive population compared to negative controls (albeit not compared to influenza populations).

All these comorbidities, alone or in combination, may put patients with COVID-19 at risk for multiorgan failure. This, together with hypoxemia owing to pulmonary changes, including diffuse alveolar damage with fibrin membranes, thickened alveolar walls, lymphocytic infiltration, 25 and pulmonary thrombosis, 25 complicated by cardiac arrhythmias, hypotensive shock, 26 and possibly brainstem dysfunction, 27 is being proposed as the final pathway to death in COVID-19. 28 Many of these mechanisms are unlikely to be specific enough to be reliably captured by diagnostic coding in EHR-based studies such as ours.

Large prospective multicenter registries and autopsy studies comparing COVID-19 patients with COVID-19-negative controls and influenza victims are required to dissect the exact contribution of each of these factors.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 28, 2020. .

being raised. 11 Yet, most (albeit not all 10 ) reports have revealed a predominance of relatively unspecific symptoms such as altered mental state in highly selected groups, 11,29,30 while we report on EHR-registered diagnoses. Our results show decreased or similar frequencies of new-onset neurological and psychiatric diagnoses in COVID-19 individuals within 30 days of testing compared to influenza, which suggests either that these complications in COVID-19 are no more frequent than in influenza or that the nationwide lockdown in Denmark resulted in fewer contacts to the health care system by people with COVID-19 but relatively mild comorbid symptoms, including neurological and psychiatric ones. Indeed, observations from California, Italy and Denmark 31-33 indicate a lower incidence of hospitalization of patients with e.g. cardiac disease during the COVID-19 lockdown. Further, mild cognitive and emotional symptoms are not likely to be reported within 30 days.

Strengths of our study are related, among others, to the large population numbers and the catchment area-based approach. The extracted general mortality data during years 2018-2020 corresponded well to Danish statistics mortality data (eTable 2). Numbers of COVID-19 and influenza tests, test results, admissions, and mortality rates in this study were equally consistent with the official Danish numbers. 34 Further, test results of SARS-CoV-2 and influenza swabs are synchronized with the Danish national microbiology database; 13 and we validated our data extraction strategy by ensuring that two individual searches supervised by two independent Epic Slicer-Dicer experts yielded identical results. As to limitations, we were unable to adjust for confounding factors such as socioeconomic, lifestyle and ethnicity, owing to the use of aggregated EHR data which depend on correct coding by physicians.

Selection bias might be considerable because individuals were tested in hospital settings (even as outpatients), and the testing strategy of COVID-19 in Denmark has been much more comprehensive compared to influenza.

In this first population-based study comparing COVID-19 with influenza, COVID-19 was associated with substantially higher mortality, which is likely even higher than the stated 3.0-5.5-fold increase owing to more extensive testing for COVID-19, and we observed higher rates of new-onset ischemic stroke, diabetes and renal failure. Next, middle-and long-term follow-up data are required to investigate mortality trajectories in COVID-19 versus influenza populations, and molecular and genetic studies will have to elucidate the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 28, 2020. .

specific biological mechanisms behind COVID-19's higher mortality and morbidity compared to influenza. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 28, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 28, 2020. https://www.sst.dk/da/corona/tal-og-overvaagning#3. Accessed July 10, 2020

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 28, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 28, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 28, 2020. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 28, 2020. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 28, 2020. Patients were followed for 30 days from positive test until end of follow-up or death. * Data presented as ≤5 is due to the General Data

Protection Regulation law restricting display of results with 5 or fewer patients, thus no statistical analysis was performed. # Percentage is calculated as new-onset diagnosis divided by sum of population excluding individuals with prior history of the investigated diagnosis.

WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard

COVID-19 Map -Johns Hopkins Coronavirus Resource Center

After Less Than 2 Months, the Simulations That Drove the World to Strict Lockdown Appear to be Wrong, the Same of the Policies They Generated

Estimates of global seasonal influenzaassociated respiratory mortality: a modelling study

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor-and angiotensin II receptor blocker-based cardiovascular therapies

Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis

COVID-19: consider cytokine storm syndromes and immunosuppression

Mounting clues suggest the coronavirus might trigger diabetes

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. The Lancet Psychiatry

The danish microbiology database (MIBA) 2010 to 2013

Clinical characteristics of coronavirus disease 2019 in China

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Characteristics and predictors of hospitalization and death in the first 9519 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark A nationwide cohort. medrxiv

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Association Between Hypoxemia and Mortality in Patients With COVID-19

Assessment of Deaths from COVID-19 and from Seasonal Influenza

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Risk of Ischemic Stroke in Patients With Reference

Patients with a positive or negative test were included in the given inclusion period. Each included patient was followed for a total of 30 days from positive test until end of follow-up or death. CLRD, Chronic lower respiratory disease

Relative mortality rates divided in inpatients and outpatients. COVID-19 negative individuals were compared as the reference group with all other study populations. COVID-19, positive COVID-19 test between

Each included patient was followed for 30 days from positive test until end of follow-up or death.* Data presented as ≤5 is due to the General Data Protection Regulation law restricting display of results with 5 or fewer patients, thus no statistical analysis was performed

Patients were followed for 30 days from positive test until end of follow-up or death. * Data presented as ≤5 is due to the General Data Protection Regulation law restricting display of results with 5 or fewer patients, thus no statistical analysis was performed